Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Breast 2

Conditions

Brain Neoplasms 4Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × paclitaxel-Angiopep-2 conjugate × Clear all
NCT02048059 2020-02-25

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Angiochem Inc

Phase 2 Completed
72 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01480583 2016-07-13

GRABM-B

Angiochem Inc

Phase 2 Completed
85 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡